TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $40.67.

TGTX has been the subject of a number of research analyst reports. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday. Finally, TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,358 shares of company stock valued at $781,497 over the last 90 days. 10.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently bought and sold shares of the business. Daymark Wealth Partners LLC increased its position in TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock worth $1,249,000 after purchasing an additional 689 shares during the last quarter. Nisa Investment Advisors LLC increased its position in TG Therapeutics by 52.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 8,112 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 2,803 shares during the last quarter. Brookstone Capital Management increased its position in TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 624 shares during the last quarter. GAMMA Investing LLC increased its position in TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 2,171 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after acquiring an additional 270,286 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 1.4 %

Shares of NASDAQ TGTX opened at $29.55 on Tuesday. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The stock has a market cap of $4.60 billion, a P/E ratio of -295.47 and a beta of 2.24. The firm has a 50-day moving average of $31.73 and a 200 day moving average of $25.79. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.73 earnings per share. As a group, sell-side analysts expect that TG Therapeutics will post 0.07 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.